ArticleCureus2025
P16 and CD44 as Biomarkers for Predicting the Progression of Immature Polypoid Squamous Metaplasia of the Cervix.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HPV Infection and Oxidative Stress in Cervical Carcinogenesis: Linking Apoptosis, Senescence, SASP, and EMT.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical intraepithelial neoplasia (CIN) is a well-established precursor of cervical cancer, while immature polypoid squamous metaplasia (IPM) has been hypothesized as a possible early lesion in cervical carcinogenesis. However, the mechanisms underlying IPM progression to CIN remain unclear. Therefore, identifying reliable biomarkers to predict progression is crucial. This study evaluates the immunohistochemical expression of P16, CD44, estrogen receptor (ER), and progesterone receptor (PR) in CIN and IPM, focusing on their prognostic significance in IPM-to-CIN progression. A total of 227 cervical tissue samples were analyzed, including CIN1 (N=30), CIN2 (N=30), CIN3 (N=32), IPM (N=60), mature squamous metaplasia (N=45), and reactive ectocervix - control (N=30). P16, CD44, ER, and PR expression were assessed immunohistochemically. Additionally, clinical HPV (human papillomavirus) status was determined via PCR, and marker expression was correlated with lesion grade using a standardized study algorithm. A subgroup of 40 IPM cases that progressed to CIN was analyzed to identify possible markers predictive of progression. Our results demonstrate that higher P16 and CD44 expression levels are significantly associated with higher-grade CIN lesions (p < 0.001). P16 and CD44 expression also strongly predicted IPM progression: P16 showed a 100% positive predictive value (PPV) for progression to CIN2 or CIN3, meaning all IPM cases with moderate or strong P16 expression advanced to high-grade CIN. CD44 had a 90% PPV for CIN progression, suggesting a strong correlation with aggressive epithelial transformation. Although ER and PR expressions were statistically significant (p < 0.05), they were not predictive markers of CIN progression. These findings highlight P16 and CD44 as possible biomarkers for identifying high-risk IPM lesions and assessing the likelihood of progression to CIN2/3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.